Stock RVX RESVERLOGIX CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Company Resverlogix Corp.

Equities

RVX

CA76128M1086

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 10:28:06 2024-04-23 am EDT 		5-day change 1st Jan Change
0.06 CAD +9.09% Intraday chart for Resverlogix Corp. +9.09% -14.29%
Apr. 01 Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 21 Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors CI

Business Summary

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Managers

Managers TitleAgeSince
Donald McCaffrey CEO
 Chief Executive Officer - 00-08-16
Anthony Cann DFI
 Director of Finance/CFO 76 09-10-25
Ewelina Kulikowski CTO
 Chief Tech/Sci/R&D Officer - 04-12-31
Michael T. Sweeney CTO
 Chief Tech/Sci/R&D Officer 63 14-11-02

Members of the board

Members of the board TitleAgeSince
Kenneth Zuerblis BRD
 Director/Board Member 64 10-09-28
Donald McCaffrey CEO
 Chief Executive Officer - 00-08-16
Kelly McNeill BRD
 Director/Board Member 54 09-10-14
Siu Lun To BRD
 Director/Board Member 55 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 274,295,571 155,820,840 ( 56.81 %) 0 44.58 %
Stock B 0 75,202,620 0 0

Shareholders

NameEquities%Valuation
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
31.34 %
85,286,524 31.34 % 4 M $
Eastern Capital Ltd.
10.18 %
27,712,879 10.18 % 1 M $
Donald McCaffrey
1.934 %
5,263,266 1.934 % 221 057 $
Anthony Cann
0.3012 %
819,755 0.3012 % 34 430 $
Michael T. Sweeney
0.0571 %
155,312 0.0571 % 6 523 $
Jan Johansson
0.0394 %
107,360 0.0394 % 4 509 $
Kenneth Zuerblis
0.0393 %
107,062 0.0393 % 4 497 $
Kelly McNeill
0.0386 %
105,000 0.0386 % 4 410 $
Ewelina Kulikowski
0.0244 %
66,500 0.0244 % 2 793 $
Aquila Capital Investmentgesellschaft mbH
0.003674 %
10,000 0.003674 % 420 $

Company contact information

Resverlogix Corp.

4820 Richard Road SW Suite 300

T3E 6L1, Calgary

+403-254-9252

http://www.resverlogix.com
address Resverlogix Corp.(RVX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RESVERLOGIX CORP. Stock Resverlogix Corp.
-14.29% 12.05M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.5B
ARGENX SE Stock argenx SE
+1.86% 22.19B
BIONTECH SE Stock BioNTech SE
-16.53% 21.33B
GENMAB A/S Stock Genmab A/S
-8.49% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RVX Stock
  4. Company Resverlogix Corp.